Final OS analysis of a phase 3 trial in 381 patients with platinum-resistant ovarian cancer: relacorilant plus nab-paclitaxel improved OS versus nab-paclitaxel alone (HR 0.65; median 16.0 v 11.9 months; 18-month OS 46% v 27%).
RCTn = 381 patients
Lorusso et al. Overall survival with relacorilant and nab-paclitaxel in patients with platinum-resistant ovarian cancer (ROSELLA): a phase 3 randomised controlled trial